https://doi.org/10.4081/monaldi.2022.2440
Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report
Submitted: September 27, 2022
Accepted: November 14, 2022
Published: November 25, 2022
Accepted: November 14, 2022
Abstract Views: 1183
PDF: 301
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Non‐small cell lung cancer (NSCLC) accounts for 75-80% of all lung cancer cases. Stage III NSCLC represents a highly heterogenous stage characterized by different disease presentations and a wide range of treatment options. For patients with good performance status and unresectable-stage III NSCLC with programmed death-ligands 1 (PD-L1) tumor proportion score (TPS) ≥1%, durvalumab consolidation immunotherapy after a platinum-based chemo-radiotherapy is strongly recommended. However, age, poor performance status, underlying comorbidities may represent contraindications for chemotherapy to be used in a subgroup of patients. Herein, we report a case of an 80-year-old male affected by a stage IIIB lung adenocarcinoma with overexpression of PD-L1 (TPS 90%) treated with pembrolizumab, an immune checkpoint inhibitor targeting PD-1/PD-L1 pathways, which shows a complete resolution of lung lesion after four cycles of treatment. Although randomized controlled trials are required, this case report may suggest the potential role of pembrolizumab for chemotherapy unsuitable patients with overexpressing PD-L1 unresectable-stage III NSCLC.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49.
DOI: https://doi.org/10.3322/caac.21660
Okawara G, Mackay JA, Evans WK, Ung YC. Management of unresected stage III non-small cell lung cancer: A systematic review. J Thorac Oncol 2006;1:377–93.
DOI: https://doi.org/10.1016/S1556-0864(15)31598-7
Perrotta F, Nankivell M, Adizie B, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer. Chest 2020;158:1230-9.
DOI: https://doi.org/10.1016/j.chest.2020.04.059
Evison M. The current treatment landscape in the UK for stage III NSCLC. Br J Cancer 2020;123:3–9.
DOI: https://doi.org/10.1038/s41416-020-01069-z
Käsmann L, Eze C, Taugner J, et al. Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: Immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol 2020;15:1-14.
DOI: https://doi.org/10.1186/s13014-020-01595-3
Komici K, Bencivenga L, Navani N, et al. Frailty in patients with lung cancer: a systematic review and meta-analysis. Chest 2022;162:485-497.
DOI: https://doi.org/10.1016/j.chest.2022.02.027
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379:2342–50.
DOI: https://doi.org/10.1056/NEJMoa1809697
Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 2020;11:10–2.
DOI: https://doi.org/10.1038/s41467-020-17670-y
Bianco A, D’Agnano V, Matera MG, et al. Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment. Expert Rev Respir Med 2021;15:1415–25.
DOI: https://doi.org/10.1080/17476348.2021.1964362
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer. N Engl J Med 2016;375:1823-33.
DOI: https://doi.org/10.1056/NEJMoa1606774
Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022;40:1301-11.
DOI: https://doi.org/10.1200/JCO.21.01308
Hass R, von der Ohe J, Ungefroren H. Impact of the tumor microenvironment on tumor heterogeneity and consequences for cancer cell plasticity and stemness. Cancers (Basel) 2020;12:3716.
DOI: https://doi.org/10.3390/cancers12123716
Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017;8:1-20.
DOI: https://doi.org/10.5306/wjco.v8.i1.1
Comella P, Frasci G, De Cataldis G, et al. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: A multicentre randomised trial. Br J Cancer 1996;74:1805-11.
DOI: https://doi.org/10.1038/bjc.1996.634
Bianco A, Malapelle U, Rocco D, et al.Targeting immune checkpoints in non small cell lung cancer. Curr Opin Pharmacol 2018;40:46-50.
DOI: https://doi.org/10.1016/j.coph.2018.02.006
Cattaneo F, Guerra G, Parisi M, Lucariello A, De Luca A, De Rosa N, et al. Expression of formyl-peptide receptors in human lung carcinoma. Anticancer Res 2015;35:2769–74.
Nigro E, Stiuso P, Matera MG, et al. The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement. Pulm Pharmacol Ther 2019;55:25-30.
DOI: https://doi.org/10.1016/j.pupt.2019.01.004
Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847–56.
DOI: https://doi.org/10.1158/1535-7163.MCT-14-0983
Incorvaia L, Fanale D, Badalamenti G, et al. Programmed death ligand 1 (PD-L1) as a predictive biomarker for pembrolizumab therapy in patients with advanced non-small-cell lung cancer (NSCLC). Adv Ther 2019;36:2600-17.
DOI: https://doi.org/10.1007/s12325-019-01057-7
Bianco A, Perrotta F, Barra G, et al. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer. Int J Mol Sci 2019;20:2931.
DOI: https://doi.org/10.3390/ijms20194931
Aguilar EJ, Ricciuti B, Gainor JF, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol 2019;30:1653-9.
DOI: https://doi.org/10.1093/annonc/mdz288
Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 2021;397:592-604.
DOI: https://doi.org/10.1016/S0140-6736(21)00228-2
Munari E, Zamboni G, Lunardi G, et al. PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. Oncotarget 2018;9:30465-71.
DOI: https://doi.org/10.18632/oncotarget.25770
Perrotta F, Rocco D, Vitiello F, et al. Immune checkpoint blockade for advanced NSCLC: A new landscape for elderly patients. Int J Mol Sci 2019;20:2258.
DOI: https://doi.org/10.3390/ijms20092258
Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 2019;135:188-95.
DOI: https://doi.org/10.1016/j.lungcan.2019.07.004
How to Cite
Medusa , Paola Maria, Marina Gilli, Luca Notizia, Raffaella Pagliaro, Nicola Carro, Alessandro Moriello, Vito D’Agnano, Andrea Bianco, Fabio Perrotta, and Fabiana Vitiello. 2022. “Complete Response to Pembrolizumab As a Single Agent in a Patient With Stage III NSCLC With High PD-L1 Expression: A Case Report”. Monaldi Archives for Chest Disease 93 (4). https://doi.org/10.4081/monaldi.2022.2440.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Mariana Gomes Tinoco, Margarida Castro, Luísa Pinheiro, Tamara Pereira, Margarida Oliveira, Sílvia Ribeiro, Nuno Ferreira, Olga Azevedo, António Lourenço, “Hot phase” clinical presentation of biventricular arrhythmogenic cardiomyopathy: when the perfect electrical storm spontaneously stops , Monaldi Archives for Chest Disease: Early Access
- Eleni D. Eleftheriadou, Maria Saroglou, Nikolaos Syrigos, Ellias Kotteas, Marousa Kouvela, The role of immunotherapy in patients with lung cancer and brain metastases: a narrative review of the literature , Monaldi Archives for Chest Disease: Early Access
- Maaha Ayub, Mustafa Bin Ali Zubairi, Najia Ghanchi, Safia Awan, Kauser Jabeen, Ali Zubairi, Pneumocystis pneumonia in HIV-positive and non-HIV patients: a retrospective comparative study from a lower-middle income country , Monaldi Archives for Chest Disease: Early Access
- Andrea Giovanni Parato, Simone D’Agostino, Simona Pelliccioni, Maria Virginia Boni, Andrea Angelini, Francesco Sbaraglia, Vito Maurizio Parato, An incidental finding of localized aortic arch dissection in a polytraumatized patient. A case report and state of the art of non-A non-B aortic dissection , Monaldi Archives for Chest Disease: Early Access
- Rakesh Behera, Sheetal Arora, Pranav Ish, Geetika Khanna, Common epidermal growth factor receptor mutations in north Indian patients with non-small cell lung carcinoma: evidence from real-time polymerase chain reaction , Monaldi Archives for Chest Disease: Early Access
- Moncef Maiouak, Vanessa Garcia-Larsen, Soumaya Benmaamar, Ibtissam El Harch, Mohamed El Biaz, Chakib Nejjari, Mohammed Chakib Benjelloun, Karima El Rhazi, Factors influencing health-related quality of life in patients with chronic obstructive pulmonary disease: insights from the Burden of Obstructive Lung Disease Study in Fez, Morocco , Monaldi Archives for Chest Disease: Early Access
- Paolo Toritto, Elena Cescutti, Igor Vendramin, Michela Puppato, Massimo Imazio, Stefano De Carli, Olga Vriz, Aortic pseudoaneurysm with a fistula between the non-coronary sinus and right atrium: a case report , Monaldi Archives for Chest Disease: Early Access
- Vasiliki Epameinondas Georgakopoulou, Nikolaos Garmpis, Dimitrios Mermigkis, Christos Damaskos, Serafeim Chlapoutakis, Konstantinos Mantzouranis, Aikaterini Gkoufa, Chrysovalantis Papageorgiou, Anna Garmpi, Sotiria Makrodimitri, Evangelos Diamantis, Pagona Sklapani, Nikolaos Trakas, Xanthi Tsiafaki, Pulmonary adverse events due to immune checkpoint inhibitors: A literature review , Monaldi Archives for Chest Disease: Vol. 92 No. 2 (2022)
- Antonietta Coppola, Anna Annunziata, Maria Rosaria Gioia, Giuseppe Fiorentino, Bleeding events in COVID-19: the other side of the coin? , Monaldi Archives for Chest Disease: Vol. 91 No. 3 (2021)
- Yusuf Kayar, Nüket Bayram Kayar, Tuncay Şahutoğlu, Venkatanarayana Gangarapu, Spontaneous pneumomediastinum following pneumonia in a 23-year-old male patient , Monaldi Archives for Chest Disease: Vol. 83 No. 1-2 (2016): Pulmonary series
<< < 14 15 16 17 18 19 20 21 22 23 > >>
You may also start an advanced similarity search for this article.
